If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
== Xenon-136 == Xenon-136 is an isotope of xenon that undergoes double beta decay to barium-136 with a very long half-life of 2.18×1021 years, approximately 11 orders of magnitude longer than the age of the universe. It is being used in the Enriched Xenon Observatory experiment to search for neutrinoless double beta decay.
Thomas's body was brought back to Wales for burial in the village churchyard at Laugharne. Thomas's funeral, which Brinnin did not attend, took place at St Martin's Church in Laugharne on 24 November. Six friends from the village carried Thomas's coffin. Caitlin, without her customary hat, walked behind the coffin with his childhood friend Daniel Jones at her arm and her mother by her side. The procession to the church was filmed and the wake took place at Brown's Hotel. Thomas's fellow poet and long-time friend Vernon Watkins wrote The Times obituary. Though Thomas died intestate, with assets worth £100, substantial royalties would accrue from sales of his work, with half the proceeds allocated to Caitlin and half to the three children. A trust was established to administer the estate and protect the copyright of Thomas's work. Trustees included Daniel Jones, Wynford Vaughan Thomas and, in an unlikely development given his low opinion of Thomas, Kingsley Amis, who was appointed at the behest of the Thomas family solicitor and administrator of the trust, Stuart Thomas. After Caitlin, troubled by painful memories, left Laugharne to live in Italy, the Thomas family home, the Boathouse, became the home of her mother-in-law, Florence, for the last five years of her life. It was subsequently purchased by the trust from Margaret Taylor on behalf of Caitlin who sold it on to an educational charity before it was eventually acquired by Carmarthenshire County Council and opened to the public as a tourist attraction.
=== James: The Boss's Son === First aired: Online James bullies fellow co-worker Sean. The only problem is that James is the boss's son. Ben Lagman submits James three times in the first round, but James survives the second round, despite taking quite a beating. This was Ben Lagman's first and, so far, only appearance in the series. The episode did not air in regular chronology and is not available on the Bully Beatdown website like most other episodes. It has been leaked on to the internet and it is unknown why the episode was not aired in the regular time slot. This episode has aired, late nights on MTV2.
Sources: en.wikipedia.org
== Early life and research == Atul Malhotra is a US citizen born in Edmonton, Alberta, Canada. He attended the University of Alberta in Canada, obtaining a bachelor's degree in Chemistry and a Medical degree in chemistry from the same university. He completed his internal medicine residency at the Mayo Clinic in Rochester, Minnesota. Malhotra does research in the domains of pulmonary medicine, intensive care unit (ICU), obstructive sleep apnea (OSA), and other respiratory biology disciplines. He studies the biology underlying the consequences of sleep apnea as well as its causation. His group uses computational modelling, cell culture techniques, rodent models, epidemiology, and clinical trials in addition to its primary focus on human physiology. Finding new therapeutic targets for sleep apnea is the main goal of his lab to meet a critical public health need. He was global principal investigator for the SURMOUNT-OSA study which led to the FDA approval of tirzepatide for treatment of moderate to severe sleep apnea in people with obesity.
Philippine Leroy-Beaulieu (French pronunciation: [filipin ləʁwa boljø]; born 25 April 1963) is a French actress. She is the daughter of actor Philippe Leroy and model Françoise Laurent. She made her screen debut in the 1983 comedy-drama film Surprise Party, before starring in the 1985 comedy film Three Men and a Cradle. She received a nomination for the César Award for Most Promising Actress for the latter role. Leroy-Beaulieu has played leading and supporting roles in more than 50 movies. In recent years, she played the title character in the RTBF crime comedy series Agathe Koltès (2016–2019); in 2020 she began starring as Sylvie Grateau in the Netflix comedy-drama series Emily in Paris.
He says he will be able to find "common ground" with the US president-elect. MP for Runcorn and Helsby, Mike Amesbury, is to be charged with common assault, following a police investigation into video footage that appeared to show him punching a man to the ground in the street. Amesbury was suspended from the Labour Party after the video emerged. 8 November – Jonathan Powell, a former Chief of Staff to Tony Blair, is appointed as the UK's national security adviser, replacing Sir Tim Barrow. 9 November – Former Health Secretary Alan Milburn, who served in the Blair government, is appointed as a non-executive director on the board of the Department of Health. 10 November – Treasury minister Darren Jones tells BBC One's Sunday with Laura Kuenssberg the UK government's commitment to Ukraine is "resolute" amid concerns Donald Trump could push the country into giving up territory to Russia once he becomes president. First Minister of Northern Ireland Michelle O'Neill becomes the first senior Sinn Féin figure to take part in an official Remembrance Sunday ceremony, held in Belfast. 11 November – The Terminally Ill Adults (End of Life) Bill, which would allow terminally ill people in England and Wales with less than six months to live to seek assistance in ending their lives, with the consent of two doctors and a High Court judge, is published. At the invitation of French president Emmanuel Macron, Starmer travels to France to mark Armistice Day at the Tomb of the Unknown Soldier, then holds talks with Macron to affirm the UK and France's commitment to supporting Ukraine.
While the amount of radiation from the plugs was minuscule and not a threat to the consumer, the benefits of such plugs quickly diminished after approximately a month because of polonium's short half-life and because buildup on the conductors would block the radiation that improved engine performance. (The premise behind the polonium spark plug, as well as Alfred Matthew Hubbard's prototype radium plug that preceded it, was that the radiation would improve ionization of the fuel in the cylinder and thus allow the motor to fire more quickly and efficiently.)
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.